AbCellera Biologics Inc. ABCL
12.10 USD +0.98 (+8.77%)
Nov 3, 2026, 3:49 PM EST
11.28 Day range 12.33
2.75 52-week range 15.02
- YTD
- +253.65%
- 1 year
- +125.23%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 17.17 +41.9% upside
Now 12.10
- Target (low)
- 9.00
- Target (mean)
- 17.17
- Target (high)
- 30.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy2
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 11
- 2 months ago 9
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.17762 | -0.20 – -0.16 | -0.19 | +6.5% | 6.25M | -30.2% | 6 |
| Next quarter | -0.17215 | -0.20 – -0.1429 | -0.03 | -473.8% | 7.05M | -84.3% | 6 |
| Current year | -0.67409 | -0.73 – -0.63 | -0.49 | -37.6% | 26.37M | -64.9% | 8 |
| Next year | -0.76251 | -0.96 – -0.56 | -0.67409 | -13.1% | 28.24M | +7.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | Initiated | — | Buy |
| Sep 29, 2026 | JP Morgan | Initiated | — | Overweight |
| Aug 11, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 6, 2026 | Stifel | Maintained | Buy | Buy |
| Aug 6, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Jul 7, 2026 | Benchmark | Upgrade | Hold | Buy |
| May 5, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Apr 10, 2026 | Jones Trading | Initiated | — | Buy |
| Nov 7, 2025 | Leerink Partners | Downgrade | Outperform | Market Perform |
| Aug 8, 2025 | Stifel | Maintained | Buy | Buy |
| Jul 14, 2025 | Keybanc | Maintained | Overweight | Overweight |
| May 16, 2025 | Truist Securities | Maintained | Buy | Buy |
| May 9, 2025 | Stifel | Maintained | Buy | Buy |
| Apr 16, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Mar 3, 2025 | Benchmark | Reiterated | Hold | Hold |
| Feb 28, 2025 | Stifel | Maintained | Buy | Buy |
| Jan 8, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Nov 5, 2024 | Benchmark | Reiterated | — | Hold |
| Nov 5, 2024 | Stifel | Reiterated | Buy | Buy |
| Aug 20, 2024 | Benchmark | Downgrade | Buy | Hold |
| Jul 11, 2024 | Keybanc | Maintained | Overweight | Overweight |
| May 8, 2024 | Keybanc | Maintained | Overweight | Overweight |
| Feb 22, 2024 | Benchmark | Upgrade | Hold | Buy |
| Feb 21, 2024 | Stifel | Maintained | Buy | Buy |
| Dec 5, 2023 | Keybanc | Initiated | — | Overweight |
| Aug 31, 2023 | Benchmark | Maintained | Buy | Buy |
| Aug 4, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| May 5, 2023 | Credit Suisse | Maintained | — | Outperform |
| Feb 28, 2023 | Cowen & Co. | Initiated | — | Outperform |
| Feb 22, 2023 | BMO Capital | Maintained | — | Outperform |